Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 pharmaceutical companies ranked by revenue, at CA$134.9B, ahead of Eli Lilly (CA$93.3B) and Merck & Co (CA$93.1B). Figures as of 18 Nov 2026, 21:37 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonCA$134.9B
- Median
- CA$4.6B
- Combined market value
- CA$7.25T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | CA$134.9B | CA$940.2B | CA$390.56 | 2.15% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | CA$93.3B | CA$1.76T | CA$1,980.37 | 2.32% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | CA$93.1B | CA$486.5B | CA$197.33 | 3.90% down | 51% up | ||
| 4 | PfizerPFE · Health Care | CA$89.6B | CA$229.1B | CA$40.19 | 1.44% down | 14% up | ||
| 5 | AbbVieABBV · Health Care | CA$87.6B | CA$724.1B | CA$409.62 | 2.33% down | 26% up | ||
| 6 | AstraZenecaAZN · Health Care | CA$84.1B | CA$397.1B | CA$256.02 | 1.93% down | 2% up | ||
| 7 | NovartisNVS · Health Care | CA$78.1B | CA$419.8B | CA$222.29 | 2.46% down | 25% up | ||
| 8 | SanofiSNY · Health Care | CA$69.3B | CA$162B | CA$67.49 | 0.86% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | CA$69B | CA$174.4B | CA$85.30 | 2.92% down | 34% up | ||
| 10 | Novo NordiskNVO · Health Care | CA$65.7B | CA$248.9B | CA$56.47 | 3.12% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | CA$63.5B | CA$259.2B | CA$149.64 | 0.22% down | 17% down | ||
| 12 | GSKGSK · Health Care | CA$62.1B | CA$139.5B | CA$69.58 | 1.34% down | 6% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | CA$40.4B | CA$97.3B | CA$30.46 | 1.71% down | 54% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | CA$24.7B | CA$70.6B | CA$60.48 | 0.92% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | CA$20.5B | CA$140.1B | CA$1,354.19 | 1.28% down | 36% up | ||
| 16 | ViatrisVTRS · Health Care | CA$20.5B | CA$33.3B | CA$29.05 | 0.83% down | 96% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | CA$17.2B | CA$194.8B | CA$768.30 | 0.42% up | 27% up | ||
| 18 | ZoetisZTS · Health Care | CA$13.6B | CA$49.8B | CA$122.55 | 2.50% up | 29% down | ||
| 19 | GrifolsGRFS · Health Care | CA$12B | CA$8.3B | CA$12.13 | 1.85% down | 1% up | ||
| 20 | BeOne MedicinesONC · Health Care | CA$7.7B | CA$66B | CA$578.04 | 2.34% down | 17% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | CA$6.8B | CA$19.1B | CA$38.24 | 3.29% up | 20% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | CA$6.1B | CA$22.8B | CA$354.86 | 2.93% up | 37% up | ||
| 23 | GenmabGMAB · Health Care | CA$5.3B | CA$45B | CA$73.00 | 1.91% down | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | CA$5.3B | CA$28.7B | CA$213.97 | 4.54% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | CA$5.1B | CA$17.9B | CA$21.45 | 1.28% up | 5% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | CA$4.6B | CA$17B | CA$87.98 | 4.99% up | 11% up | ||
| 27 | United TherapeuticsUTHR · Health Care | CA$4.6B | CA$35.2B | CA$826.87 | 1.16% down | 23% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | CA$4.3B | CA$10.9B | CA$31.34 | 3.60% up | 83% up | ||
| 29 | Royalty PharmaRPRX · Health Care | CA$3.4B | CA$56.5B | CA$98.35 | 0.01% down | 78% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | CA$2.5B | CA$7.2B | CA$86.26 | 0.22% down | 20% down | ||
| 31 | AlkermesALKS · Health Care | CA$2.1B | CA$11.3B | CA$67.10 | 3.08% up | 58% up | ||
| 32 | Legend BiotechLEGN · Health Care | CA$1.5B | CA$4.5B | CA$23.27 | 0.87% up | 42% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | CA$1.4B | CA$13.2B | CA$570.13 | 5.67% down | 24% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | CA$1.4B | CA$6.5B | CA$39.23 | 1.59% up | 64% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | CA$1.2B | CA$8.7B | CA$61.74 | 0.28% up | 10% up | ||
| 36 | Ascendis PharmaASND · Health Care | CA$1.1B | CA$25.4B | CA$387.17 | 0.32% down | 28% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | CA$1.1B | CA$10.6B | CA$97.09 | 3.25% down | 8% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CA$970.4M | CA$10.7B | CA$136.13 | 0.06% down | 126% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | CA$914.5M | CA$10.1B | CA$191.91 | 1.43% down | 7% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | CA$882.6M | CA$14.3B | CA$94.70 | 5.44% up | 107% up | ||
| 41 | InsmedINSM · Health Care | CA$868.5M | CA$37.6B | CA$171.58 | 1.69% down | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | CA$746.6M | CA$8.6B | CA$132.46 | 0.59% up | 31% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | CA$719.1M | CA$21.8B | CA$111.73 | 1.58% up | 17% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | CA$702.8M | CA$6.9B | CA$71.95 | 1.68% down | 44% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | CA$384M | CA$8.6B | CA$427.81 | 1.67% up | 43% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | CA$271.8M | CA$11.8B | CA$170.49 | 2.08% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | CA$126.1M | CA$10.2B | CA$73.50 | 0.64% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | CA$65.9M | CA$11.9B | CA$182.12 | 2.00% up | 46% up | ||
| 49 | Roivant SciencesROIV · Health Care | CA$11.8M | CA$40.2B | CA$55.47 | 0.05% up | 90% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | CA$2.9M | CA$6.8B | CA$120.28 | 3.45% down | 113% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | CA$0 | CA$13.8B | CA$145.31 | 8.15% up | 286% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | CA$0 | CA$12.2B | CA$437.09 | 0.04% up | 61% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 1.4322 CAD). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by revenue?
Johnson & Johnson (CA$134.9B), Eli Lilly (CA$93.3B) and Merck & Co (CA$93.1B) are the top three of the 52 pharmaceutical companies ranked by revenue as of 18 Nov 2026, 21:37 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of CA$7.25T as of 18 Nov 2026, 21:37 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.